Barclays Starts IDEXX Laboratories (IDXX) at Overweight

Barclays analyst Glen Santangelo initiates coverage on IDEXX Laboratories (NASDAQ: IDXX) with a Overweight rating and a price target of $850.00.

For an analyst ratings summary and ratings history on IDEXX Laboratories click here. For more ratings news on IDEXX Laboratories click here.

Shares of IDEXX Laboratories closed at $714.10 yesterday.

You May Also Be Interested In

• IDEXX launches point-of-care cardiac test for cats and dogs
• JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
• Evercore ISI Starts Alvotech SA (ALVO) at Outperform